Literature DB >> 9438229

Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.

A Dubini1, M Bosc, V Polin.   

Abstract

The outcome of antidepressant therapy in terms of social functioning was evaluated in a randomized, placebo-controlled, double-blind study comparing the selective noradrenaline reuptake inhibitor (NARI), reboxetine, with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Of the 381 patients with major depression participating in the study, 302 patients were assessed using the new self-rating Social Adaptation Self-evaluation Scale (SASS). Mean SASS total score at last assessment was superior (p < 0.05) to placebo for both reboxetine and fluoxetine. Moreover, reboxetine was superior (p < 0.05) to fluoxetine. Evaluation of the sensitivity to change in individual items by point-biserial correlation analysis showed a significant correlation between improvement in item score and reboxetine treatment in all but one item for the reboxetine-placebo comparison. In the fluoxetine-placebo comparison, a significant correlation was evident for only 12 of the 21 items. Direct comparison of reboxetine with fluoxetine revealed a significant correlation between change in item score and treatment for nine items, in favour of reboxetine. The association was maximal for six items, mainly related to negative self-perception and to active social behaviour. In the subset of patients in remission at last assessment (n = 91), the mean SASS total score for reboxetine was superior to that of both fluoxetine and placebo (p < 0.05). Point-biserial correlation analysis revealed that most items sensitive to change under active treatment in the total population did so with reboxetine (17 items) or fluoxetine (nine items) in patients in remission. In the reboxetine-fluoxetine comparison, 14 items showed a significant association with reboxetine treatment. In conclusion, while social motivation and behaviour in depression are significantly affected by both noradrenergic and serotonergic antidepressant treatment, noradrenergic therapy seems particularly effective in improving negative self-perception and motivation towards action, resulting in a better quality of remission in terms of social functioning.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9438229

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  16 in total

Review 1.  Third-generation antidepressants: do they offer advantages over the SSRIs?

Authors:  J S Olver; G D Burrows; T R Norman
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Adrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilin.

Authors:  Wenhua Liu; Eunice Y Yuen; Patrick B Allen; Jian Feng; Paul Greengard; Zhen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

Review 3.  Defining and measuring functional recovery from depression.

Authors:  Tracy L Greer; Benji T Kurian; Madhukar H Trivedi
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

4.  Peer social interaction is facilitated in juvenile rhesus monkeys treated with fluoxetine.

Authors:  Mari S Golub; Casey E Hogrefe; Alicia M Bulleri
Journal:  Neuropharmacology       Date:  2016-02-22       Impact factor: 5.250

5.  The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety.

Authors:  N L Schramm; M P McDonald; L E Limbird
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

6.  Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.

Authors:  Liborio Rampello; Santina Chiechio; Giovanni Nicoletti; Alessandro Alvano; Ignazio Vecchio; Rocco Raffaele; Mariano Malaguarnera
Journal:  Psychopharmacology (Berl)       Date:  2003-12-17       Impact factor: 4.530

Review 7.  Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.

Authors:  Dirk Eyding; Monika Lelgemann; Ulrich Grouven; Martin Härter; Mandy Kromp; Thomas Kaiser; Michaela F Kerekes; Martin Gerken; Beate Wieseler
Journal:  BMJ       Date:  2010-10-12

8.  Patient-reported functioning in major depressive disorder.

Authors:  Waguih William IsHak; David M James; James Mirocha; Haidy Youssef; Gabriel Tobia; Sarah Pi; Katherine L Collison; Robert M Cohen
Journal:  Ther Adv Chronic Dis       Date:  2016-03-31       Impact factor: 5.091

Review 9.  Depression in adults: drug and physical treatments.

Authors:  Corrado Barbui; Rob Butler; Andrea Cipriani; John Geddes; Simon Hatcher
Journal:  BMJ Clin Evid       Date:  2007-06-15

10.  Reboxetine: a preliminary report on its use through the Special Access Program.

Authors:  Sidney H Kennedy; Raymond W Lam; Nicole L Cohen; Michael Rosenbluth; Stephen T H Sokolov; Roger S McIntyre; Pierre Chue; Gerry Craigen
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.